ADMA
Adma Biologics Inc
Adma Biologics Inc
$ADMA reports record revenue growth, opportunities for future earnings, and expanded product portfolio.
ADMA Biologics reports Q4 revenue of $50.2M due to increased sales of ASCENIV, leading to record number of patients treated and strong market share gains. The focus on immune-deficient patient segment could lead to potential revenue and earnings growth beyond prior guidance. Positive EBITDA is expected in H2 2023. The company aims to drive profitability ahead, and expects favorable product mix to continue. Expansion of product portfolio is also planned.
2d ago
$ADMA